Loading...
EVO logo

Evotec SENasdaqGS:EVO Stok Raporu

Piyasa Değeri US$953.9m
Hisse Fiyatı
US$2.70
US$3.77
28.3% değerinin altında içsel indirim
1Y-33.5%
7D-12.1%
Portföy Değeri
​
Görünüm

Evotec SE

NasdaqGS:EVO Stok Raporu

Piyasa değeri: US$953.9m

Evotec (EVO) Hisse Özeti

Evotec SE, Amerika Birleşik Devletleri, Almanya, Fransa, Birleşik Krallık, İsviçre ve uluslararası alanda bir ilaç keşif ve geliştirme şirketi olarak faaliyet göstermektedir. Daha fazla detay

Ödüller

Adil değer tahminimizden 48.3% daha düşük bir oranda işlem görüyor

Kazançların yılda 72.71% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Risk kontrollerimizden EVO için herhangi bir risk tespit edilmedi.

EVO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Evotec SE Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Evotec
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı€2.70
52 Haftanın En Yüksek Seviyesi€4.80
52 Haftanın En Düşük Seviyesi€2.31
Beta1.3
1 Aylık Değişim-15.89%
3 Aylık Değişim-23.08%
1 Yıllık Değişim-33.50%
3 Yıllık Değişim-74.77%
5 Yıllık Değişim-86.58%
Halka arzdan bu yana değişim149.42%

Son Haberler & Güncellemeler

Recent updates

Seeking Alpha • Jul 23

Evotec: Recovery Seems To Be Beginning

Summary Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, expanding Evotec Biologics, leveraging AI, and executing cost-saving measures to improve profitability. Despite high leverage and recent revenue declines, strong partnerships, a robust pipeline, and operational improvements support my continued investment thesis. Risks are significant, but Evotec's growth prospects and current valuation justify maintaining my position for potential outsized returns over several years. Read the full article on Seeking Alpha
Seeking Alpha • Dec 29

Evotec: Some Recovery Has Come, But Much More Is Expected

Summary Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside. I maintain a price target of €20/share ($11/share for the Nasdaq ticker), viewing Evotec as a speculative investment with a risk/reward-adjusted upside. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Evotec: Weak Performance, But Long-Term Potential Is There

Summary Evotec's 28% decline is due to negative EBITDA despite solid top-line revenue growth, highlighting the need for patience in speculative investments. The company is restructuring, focusing on biologics and partnerships with BMY and others, aiming for profitability by 2025 or later. Valuation remains tricky; I cut my price target to $11/share due to delayed market recovery and sluggish revenue recognition. Evotec is a speculative "buy" with high potential but significant risks; I recommend holding and watching for now, not buying more. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Evotec: Still A Speculative Buy After A Significant Decline

Summary Evotec SE's stock has declined over 30% in a single day, marking a 5-year decline of over 56%. The company's 2023A results met guidance, but the market expected more from the 2024E forecasts. The change in reporting structure and the stepping down of the CEO have also contributed to the decline in share price. I am still saying "Spec BUY", but with care. Read the full article on Seeking Alpha
Seeking Alpha • Oct 17

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Toronto Innovation Acceleration Partners (TIAP) and Evotec (NASDAQ:EVO) said the two companies expanded their translational BRIDGE partnership LAB150, to include Amgen (NASDAQ:AMGN) as a strategic partner. The expansion goes along with a combined investment of $14M to expedite LAB150 programs for forming new life science companies, Evotec said in a statement on Monday. TIAP and Evotec created LAB150 in 2017 to accelerate Toronto's academic research into market-ready products. Amgen will provide financial support for chosen LAB150 projects and mentorship from its drug discovery and development teams. In addition, Amgen Ventures will evaluate LAB150-derived companies for venture investment, Evotec noted. "Together with Evotec, we look forward to collaborating with Amgen to bring enhanced expertise and capital to LAB150 to enable life science company creation,” said TIAP President and CEO Parimal Nathwani.
Seeking Alpha • Sep 20

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) said the U.S. Department of Defense (DOD) awarded it a contract worth up to $49.9M for the rapid development of monoclonal antibody (mAb)-based drug product prototypes targeting plague. Under the agreement, Evotec's Seattle-based unit Just - Evotec Biologics will develop mAb-based drug product prototype(s) from sequence discovery or evaluation of existing mAbs to completion of phase 1 first-in-human (FIH) trials, the company said in a Sept. 20 press release. To enable rapid development, Just - Evotec will use its data-driven, automated biologics technology platform J.DESIGN and continuous manufacturing at its J.POD Redmond, Washington (U.S.) facility. Evotec will also provide pre-clinical and clinical capabilities for mAb prophylactic approvals. The contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies within the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in collaboration with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). EVO -5.24% to $9.41 premarket Sept. 20
Seeking Alpha • Aug 25

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) is acquiring Central Glass Germany from Japanese chemical manufacturing company Central Glass Co. to expands its clinical and commercial manufacturing platform for small molecule therapeutics. Germany-based Evotec said in an Aug. 25 press release that the contract was signed on Aug. 24 at a purchase price of €1. Evotec added it intends to invest in the coming years to establish the facility as a European center of excellence for rare disease drug substance manufacturing. Evotec said Central Glass will now operate as Evotec Drug Substance (Germany) GmbH (Evotec DS). Central Glass is located on a pharmaceutical manufacturing campus in Halle/Westphalia and has a team of ~60 chemical manufacturing experts. The transaction is expected to close on Nov. 1, subject to conditions. Evotec noted that earnings accretion is expected to be achieved by 2023/24. EVO +1.11% to $11.87 premarket Aug. 25
Seeking Alpha • Aug 10

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Evotec (NASDAQ:EVO) said its Seattle-based unit Just - Evotec Biologics expanded a multi-year partnership with Alpine Immune Sciences (NASDAQ:ALPN) to develop a commercial process for ALPN-303. Evotec said ALPN-303 is being developed to treat systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of the companies first-in-human program initiated in 2020 in which Just - Evotec delivered drug substance materials for Alpine's ongoing phase 1 study and anticipated phase 2 studies of ALPN-303. Under the expanded contract, Just - Evotec Biologics will use its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. The program includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN‑303. Commercial process development activities will be undertaken at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington. EVO -10.15% to $12.66 premarket Aug. 10
Seeking Alpha • Jul 06

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Boehringer Ingelheim, Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and bioMérieux formed a joint venture called Aurobac Therapeutics SAS to develop antimicrobials and diagnostics to fight Antimicrobial Resistance (AMR). Aurobac, which will develop a new precision medicine approach from diagnosis to cure, was funded with €40M in total with Boehringer Ingelheim investing €30M and Evotec and bioMérieux funding €5M each, according to the companies' July 6 press release. "Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results," said bioMérieux Chairman and CEO Alexandre Mérieux. Boehringer's participation in Aurobac is part of a wider pandemic preparedness initiative, which includes a €50M investment in AMR. Boehringer Ingelheim Venture Fund has committed to invest up to €12M in AMR infection companies.

Hissedar Getirileri

EVOUS Life SciencesUS Pazar
7D-12.1%-5.8%-0.9%
1Y-33.5%-1.1%24.4%

Getiri vs. Endüstri: EVO geçen yıl % -1.1 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.

Getiri vs Piyasa: EVO geçen yıl % 24.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is EVO's price volatile compared to industry and market?
EVO volatility
EVO Average Weekly Movement8.9%
Life Sciences Industry Average Movement8.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: EVO son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: EVO 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
19934,526Christian Wojczewskiwww.evotec.com

Evotec SE, Amerika Birleşik Devletleri, Almanya, Fransa, Birleşik Krallık, İsviçre ve uluslararası alanda bir ilaç keşif ve geliştirme şirketi olarak faaliyet göstermektedir. Ortak Ar-Ge ve Just - Evotec Biologics olmak üzere iki segmentte faaliyet göstermektedir. Şirket onkoloji, otoimmün, kanser, diyabet, kalp yetmezliği, immünoloji, ağrı ve enflamasyon, enfeksiyöz, böbrek, karaciğer, solunum, fibrotik ve metabolik hastalıklar ve nadir hastalıklar gibi çeşitli terapötik alanlarda farmasötik ürünler geliştirmektedir.

Evotec SE Temel Bilgiler Özeti

Evotec'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
EVO temel i̇stati̇sti̇kler
Piyasa değeriUS$953.92m
Kazançlar(TTM)-US$225.31m
Gelir(TTM)US$865.82m
1.1x
P/S Oranı
-4.2x
F/K Oranı

EVO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
EVO gelir tablosu (TTM)
Gelir€745.04m
Gelir Maliyeti€665.62m
Brüt Kâr€79.42m
Diğer Giderler€273.29m
Kazançlar-€193.88m

Son Raporlanan Kazançlar

Mar 31, 2026

Sonraki Kazanç Tarihi

Aug 13, 2026

Hisse başına kazanç (EPS)-1.09
Brüt Marj10.66%
Net Kâr Marjı-26.02%
Borç/Özkaynak Oranı55.4%

EVO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/15 12:55
Gün Sonu Hisse Fiyatı2026/05/15 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Evotec SE 23 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Christian EhmannBerenberg
Michael RyskinBofA Global Research
Peter VerdultCitigroup Inc